Efficacy of Detoxsan® powder on diarrhea caused by gastrointestinal neuroendocrine tumors

doi:10.3748/wjg.v25.i17.2133

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 25, Issue 17

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (9902)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-5) series.

Item

Count

PDF

405

WORD

198

HTML

5732

Figures (1-3)

309

Tables (1-5)

303

Sum=6947

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1168

Download

1787

Sum=2955

May 7, 2019 (publication date) through Feb 27, 2025

Times Cited of This Article

Times Cited (4)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Observational Study

World J Gastroenterol. May 7, 2019; 25(17): 2133-2143
Published online May 7, 2019. doi: 10.3748/wjg.v25.i17.2133

Table 1 Patient cohort

Patient	Female	Male	Age (yr)	Grading	Functionality	Resection (cm)	HBP	Others
1	X		55	G2	yes, WD	IL, 62 + CC, 4		X
2		X	68	G2	yes, WD	IL, 40	X	X
3	X		72	G2	yes, WD	IL, 56 + CO, 11	X	X
4	X		79	G1	yes, WD	ileocecal		X
						IL + jejunum, 150
5	X		60	G1	yes, WD	hemicolectomy	X	X
6	X		65	G2	yes, WD	hemicolectomy		X
7	X		47	G2	yes, WD	hemicolectomy, 220		X
8		X	77	G1	yes, WD	hemicolectomy, 120		X
9	X		43	G2	no, WD	no		X
10		X	61	G2	MD, Serotonin	ileocecal, 40		X
11	X		73	G1	yes, WD	hemicolectomy, IL		X
12		X	57	G1	yes, WD	mid IL		X
13		X	63	G2	yes, WD	IL segments	X	X
14	X		48	G2	yes, WD	IL, 23 + CO, 31	X	X
15		X	64	G2	yes, WD	IL, 70	X
16		X	77	unknown	WD, Chromogranin	IL, 64		X
17	X		74	G2	yes, WD	IL, 18		X
18	X		78	unknown	yes, WD	no	X	X
19		X	83	G1	Chromogranin	no		X
20	X		39	G1	no, well diff.	no	X	X
Total	12	8
Average age	61.1	68.7	64.1

Grading: Of neuroendocrine tumors according to WHO classification[29]; WD: Well-differentiated neuroendocrine neoplasm; MD: Moderately-differentiated neuroendocrine neoplasm; CC: Coecum; CO: Colon; IL: Ileum; HBP: Hypertension or high blood pressure.

Table 2 Clinical parameters of the patients

Patient	Nutricion	Somatostatin	Dosage	Interval	Loperamide¹	Disease	NET type	Primary			Metastases	in		PRRT
	consultation	analog				stage			Liver	Lymph	Bone	Lung	Peritoneum

1	yes	OCT	30 mg	4 wk	if required	IV	functional	midgut	x	x			x	2^nd
2	yes	OCT	20 mg	4 wk	if required	IIIb	functional	midgut	x	x			x	3^rd
3	yes	OCT	30 mg	4 wk	no	IV	functional	midgut	x	x	x		x	2^nd
4	yes	LAN	120 mg	6 wk	no	IV	functional	midgut	x	x	x	x		2^nd
5	yes	LAN	120 mg	3 wk	no	IV	functional	midgut	x		x			2^nd
6	yes	OCT	30 mg	4 wk	no	IIIb	functional	midgut	x	x				4^th
7	yes	OCT	30 mg	4 wk	no	IIIb	functional	midgut	x	x				3^rd
8	yes	LAN	120 mg	4 wk	if required	IV	functional	midgut	x	x				2^nd
9	yes	no			no	IV	nonfunctional	pancreas	x	x	x			1^st
10	yes	OCT	30 mg	4 wk	no	IV	functional	midgut	x	x	x			3^rd
		OCT s.c.	+ 100 µg	if required
11	yes	OCT	30 mg	4 wk	no	IIIb	functional	midgut	x				x	1^st
12	yes	LAN	120 mg	4 wk	if required	IV	functional	midgut		x				2^nd
13	yes	OCT	30 mg	4 wk	if required	IV	functional	midgut	x					3^rd
14	yes	LAN	120 mg	4 wk	no	IV	functional	appendix		x				2^nd
15	yes	OCT	30 mg	4 wk	no	IV	functional	midgut	x	x			x	3^rd
16	yes	OCT	20 mg	4 wk	if required	IV	functional	midgut	x				x	2^nd
17	yes	LAN	120 mg	4 wk	if required	IIIb	functional	midgut	x	x	x			2^nd
18	yes	OCT	30 mg	3 wk	if required	IV	functional	CUP	x	x				3^rd
19	yes	OCT	30 mg	4 wk	no	IV	nonfunctional	pancreas	x		x		x	1^st
20	yes	OCT	30 mg	4 wk	no	IV	functional	CUP	x	x				3^rd

¹During treatment with Detoxsan^® powder. OCT: Octreotide (Sandostatin LAR); LAN: Lanreotide (Somatuline Autogel); CUP: Unknown primary with suspicion of midgut primary; PRRT: Peptide receptor radionuclide therapy as treatment line. Determination of the disease stage according to the WHO classification[29].

Table 3 Effect of Detoxsan^® powder on the bowel movements as evaluated by patients

Patient	Empirical evaluation of the patients			Intake time (d)	Dose (g/d)	Bowel movement
	Satisfied	Uncertain	Non-satisfied			(frequency per day)
1			X	41	4 x 5	9 to 12
2			X	10	6 x 3	8 to 11
3	X			160	1 x 3	1 to 3
4		X		118	3 x 3	2 to 3
5	X			201	3 x 3	3 to 5
6		X		106	3 x 3	1 to 3
7	X			215	2 x 2	3
8	X			605	2 x 2	1 to 3
9	X			21	3 x 1	1 to 2
10	X			134	2 x 2	3 to 5
11	X			220	3 x 1	2 to 3
12	X			427	2 x 3	2 to 3
13	X			138	2 x 2	1 to 2
14	X			31	2 x 3	2 to 4
15	X			21	1 x 3	1 to 2
16	X			31	1 x 5	1
17			X	20	2 x 3	6 to 7
18		X		62	2 x 3	3 to 4
19	X			31	1 x 3	1 to 2
20	X			31	2 x 3	1 to 3
Total	15	3	3
Percentage	70.0	15.0	15.0

Responses were categorized as: Satisfied-bowel movements significantly reduced, uncertain-bowel movements not permanently reduced and non-satisfied-no improvement of defecation number.

Table 4 Diary of a 57-year-old male patient using Detoxsan^® powder over 3 mo

Detoxsan^® powder intake (d)	days	Dose (g/d)	Bowel movements (frequency per day)	Empirical evaluation, daily
Detoxsan^® powder intake (d)	days	Dose (g/d)	Bowel movements (frequency per day)	Satisfied	Non-satisfied
1 to 2		2 x 2	5 to 8		2
	3 to 8	2 x 2	1 to 4	6
9 to 11		2 x 2	5 to 8		3
12 to 13		2 x 3	5 to 8		2
	14 to 26	2 x 2	1 to 4	13
27 to 28		2 x 2	5 to 8		2
	29 to 31	2 x 2	1 to 4	3
	32 to 43	2 x 3	1 to 4	12
44 to 49		2 x 3	5 to 8		6
	50 to 75	2 x 3	1 to 4	26
76 to 79		2 x 3	5 to 8		4
	80 to 87	2 x 3	1 to 4	8
88 to 91		2 x 3	5 to 8		4
	92 to 120	2 x 3	1 to 4	28
Sum of days				96	23

The dose of Detoxsan^® powder was individually adjusted. The treatment effect was assessed by the patient himself.

Table 5 Blood parameters determined before (in brackets) and after the application of Detoxsan^® powder

Patient	Serotonin (µg/L)	Creatinine (µmol/L)	Urea (mmol/L)	Sodium (mmol/L)	Potassium (mmol/L)	Calcium (mmol/L)
1	(1.554) 2.442	(58.0) 62.4	(3.1) 2.7	(139) 134	(3.7) 5.2	(2.3) 2.2
2	(ND) 940	(126.7) 142.3	(5.5) 7.3	(139) 142	(4.0) 4.2	(2.4) 2.4
3	(289) 530	(59.0) 69.8	(4.1) 5.2	(138) 133	(4.9) 4.4	(2.3) 2.2
4	(919) 718	(75.0) 92.1	(4.0) 4.8	(134) 140	(3.9) 4.0	(2.2) 2.3
5	(1.834) 1.330	(57.9) 91.9	(4.4) 5.4	(144) 145	(4.2) 3.9	(2.3) 2.3
6	(398) 540	(72.8) 91.8	(7.8) 10.4	(141) 137	(4.3) 4.1	(2.0) 2.1
7	(ND) 318	(53.0) 46.0	(3.1) 3.1	(139) 139	(3.9) 3.4	(2.3) 2.1
8	(946) 399	(167.5) 204.7	(4.7) 9.9	(142) 145	(4.2) 5.0	(2.3) 2.1
9	(394) 575	(73.2) 66.9	(3,7) 5.1	(136) 138	(4.3) 4.4	(2.3) 2.3
10	(2.500) 688	(60.5) 83.7	(3.6) 3.8	(146) 142	(3.8) 4.5	(2.3) 2.3
11	(263) 1.939	(59.3) 93.8	(6.8) 6.5	(144) 142	(4.3) 4.2	(2.1) 2.0
12	(1.102) 1.025	(85.6) 70,6	(4.1) 3.4	(143) 142	(3.9) 3.2	(2.2) 2.2
13	(1.230) 708	(70.0) 69.5	(5.4) 3.5	(144) 145	(4.0) 4.3	(2.4) 2.5
14	(1.967) 775	(46,9) 54,9	(2.6) 3.2	(142) 143	(4.4) 4.3	(2.3) 2.3
15	(2.052) 2.500	(75.1) 110.7	(4.6) 6.3	(137) 141	(3.9) 3.8	(2.3) 2.3
16	(477) 353	(58.6) 55.9	(5.8) 7.0	(144) 146	(4.2) 4.8	(2.2) 2.4
17	(1.224) 1.446	(50.3) 48.3	(3.5) 3.9	(143) 142	(4.0) 4.0	(2.3) 2.3
18	(1.185) 2.500	(52.7) 61.6	(3.5) 3.4	(143) 140	(4.2) 4.3	(2.3) 2.3
19	95 (63)	(155.0) 171.5	(8.2) 13.9	(133) 137	(4.1) 4.6	(2.3) 2.3
20	68 (64)	(75.5) 74.3	(5.3) 5.8	(144) 142	(4.5) 4.1	(2.4) 2.4

Bold values indicate that parameters were determined within a short time interval (< 30 d) before and after using Detoxsan^® powder, respectively.

Citation: Langbein T, Dathe W, Deuerling A, Baum RP. Efficacy of Detoxsan^® powder on diarrhea caused by gastrointestinal neuroendocrine tumors. World J Gastroenterol 2019; 25(17): 2133-2143
URL: https://www.wjgnet.com/1007-9327/full/v25/i17/2133.htm
DOI: https://dx.doi.org/10.3748/wjg.v25.i17.2133